Results 111 to 120 of about 651,817 (302)

Study design considerations to assess the impact of potential drug–drug interactions in first‐in‐human studies in oncology drug development

Clinical and Translational Science, 2023
Sriram Subramaniam, Stacy S. Shord, Ruby Leong, Kelly Norsworthy, Atiqur Rahman, Brian Booth, Olanrewaju Okusanya   +6 more
doaj   +1 more source

Heterogeneity of Rheumatoid Arthritis–Associated Interstitial Lung Disease by Longitudinal Forced Vital Capacity Trajectory and Associations With Disease Outcomes

Arthritis Care &Research, EarlyView.
Objective We aimed to identify unique disease trajectories within rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) based on longitudinal forced vital capacity (FVC) values and their associated clinical outcomes. Methods We performed a cohort study of RA‐ILD within the Veterans Health Administration from 1999 to 2021.
Bryant R. England, Yangyuna Yang, Punyasha Roul, Tate M. Johnson, Scott M. Matson, Grant W. Cannon, Brian C. Sauer, Jeffrey R. Curtis, Joshua F. Baker, Ted R. Mikuls   +9 more
wiley   +1 more source

Morphologic, Biologic, and Cytochemical Analysis of Intracytoplasmic Particles Found in Cultured Fibroblasts from Patients with Systemic Lupus Erythematosus**From the Division of Virology, Bureau of Biologies, Food and Drug Administration, †the Laboratory of Pathology, National Cancer Institute, NIH, and ‡the Arthritis and Rheumatism Branch, National Institute of Arthritis Metabolosm and Degestive Diseases, NIH, Cethesda, Maryland 20014.

, 1974
David W. Barry, Zsuzsa Schaff, Philip M. Grimley, Hope E. Hopps, Robert G. Aptekar   +4 more
openalex   +1 more source

Long‐Term Opioids in Gout: A Matched Cohort Study From the Veterans Health Administration

Arthritis Care &Research, EarlyView.
Objective Though used frequently to treat flare, risk of long‐term opioid exposure in gout has not been well defined. In this study, we examined the hypothesis that people with gout are more likely than individuals without gout to be prescribed long‐term opioids over time.
Lindsay N. Helget, Bryant R. England, Punyasha Roul, Harlan Sayles, Tuhina Neogi, James R. O'Dell, Joshua F. Baker, Ted R. Mikuls   +7 more
wiley   +1 more source

Use, Safety, and Efficacy of Single-Patient Use of the US Food and Drug Administration Expanded Access Program [PDF]

, 2019
Noah Z. Feit, Debra A. Goldman, Evan Smith, Jenny Deighan, Alexia Iasonos, Oliver Zivanovic, David M. Hyman   +6 more
openalex   +1 more source

Preferences for post‐traumatic osteoarthritis prevention strategies in individuals with anterior cruciate ligament injury

Arthritis Care &Research, Accepted Article.
Objectives There is growing interest in evaluating new strategies to delay or prevent post‐traumatic osteoarthritis (PTOA) in individuals who have sustained anterior cruciate ligament (ACL) injury. This study sought to determine characteristics of potential treatments that are acceptable to patients with ACL injury.
Kevin Kennedy, Lily Waddell, Adam Easterbrook, Jeffrey N. Katz, Cale Jacobs, Morgan Jones, Faith Selzer, Elena Losina, Liana Fraenkel, Nick Bansback   +9 more
wiley   +1 more source

The Food and Drug Administration as Gatekeeper and the Menthol Exemption

, 2020
Micah L. Berman, Desmond Jenson
openalex   +2 more sources

Clinical Outcomes of Patients Within the Rheumatoid Arthritis Care Pathway Cohort at a Tertiary Care Integrated Delivery Network: A Comparison to Usual Care

Arthritis Care &Research, EarlyView.
Objective We aimed to compare clinical outcomes between patients in the Allegheny Health Network rheumatoid arthritis (RA) care pathway and patients receiving usual care. Methods The care pathway initiative implements guideline‐based best practice alongside multidisciplinary team‐based care.
Tarun Sharma, Tyson S. Barrett, Teigan Dwyer, Nancy Campbell, Jessica Heintzinger, Ellen Kraemer, Adam Dore, Susan Manzi   +7 more
wiley   +1 more source

Food And Drug Administration [PDF]

, 2020
openaire   +2 more sources

Policies to improve access to pharmaceutical products in shortage: the experience of Iran food and drug administration [PDF]

, 2019
Nazila Yousefi, Najmeh Moradi, Rassoul Dinarvand, Golbarg Ghiasi, Hamidreza Inanloo, Farzad Peiravian   +5 more
openalex   +1 more source